Filing Details

Accession Number:
0000884731-16-000083
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-05 16:07:56
Reporting Period:
2016-07-01
Filing Date:
2016-07-05
Accepted Time:
2016-07-05 16:07:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
884731 Ariad Pharmaceuticals Inc ARIA Biological Products, (No Disgnostic Substances) (2836) 223106987
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242992 P Timothy Clackson C/O Ariad Pharmaceuticals Inc
26 Landsdowne Street
Cambridge MA 02139
President, R&D, Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-01 31,422 $4.49 297,916 No 4 M Direct
Common Stock Disposition 2016-07-01 31,422 $7.48 266,494 No 4 S Direct
Common Stock Acquisiton 2016-07-01 30,000 $3.25 296,494 No 4 M Direct
Common Stock Disposition 2016-07-01 30,000 $7.48 266,494 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-07-01 31,422 $4.49 31,422 $4.49
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-07-01 30,000 $3.25 30,000 $3.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2008-04-16 2017-04-16 No 4 M Direct
0 2011-06-25 2020-06-24 No 4 M Direct
Footnotes
  1. Shares were acquired from exercise of an outstanding stock option pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2015
  2. Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2015
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.315 to $7.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.